Published • loading... • Updated
AI-designed first-in-class small-molecule inhibitor shows preclinical
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AI-designed first-in-class small-molecule inhibitor shows preclinical
Jacksonville, Fla. — Mayo Clinic researchers have used artificial intelligence to identify an experimental small-molecule drug that targets a protein region long considered difficult to treat. The compound is designed to block the PDZ domain of GIPC1, a protein that supports the growth, survival and treatment resistance of several cancers, including pancreatic ductal adenocarcinoma. In […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
